A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
Investor's Business Daily on MSN
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year
Shares of Ligand PharmaceuticalsLGND are absolutely flying, up more than 92% this year, as investors line up behind the ...
The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $42.33 / share. This is an ...
Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...
Michael Burry Shutters Scion Asset Management, Renews AI Bubble Warning With Lord of the Rings Meme (International Business ...
The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results